Contrary to the pan-HDAC inhibitor vorinostat, selective inhibition of HDAC6 may impair the cytotoxic capacity of CD8 T cells, as tumor-specific CD8 T cells from mice treated with the HDAC6-specific inhibitor tubastatin A and the HDAC6-deficient mice showed reduced lytic capacity of CD8 T cells, probably due to interrupted intracellular trafficking and exocytosis of perforin [144]. This evidence concerns the gene PRF1 and neoplasm.